These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 24477930

  • 1. Development of single vial kits for preparation of (68)Ga-labelled peptides for PET imaging of neuroendocrine tumours.
    Mukherjee A, Pandey U, Chakravarty R, Sarma HD, Dash A.
    Mol Imaging Biol; 2014 Aug; 16(4):550-7. PubMed ID: 24477930
    [Abstract] [Full Text] [Related]

  • 2. Development and Evaluation of User-Friendly Single Vial DOTA-Peptide Kit Formulations, Specifically Designed for Radiolabelling with 68Ga from a Tin Dioxide 68Ge/68Ga Generator.
    Prince D, Rossouw D, Davids C, Rubow S.
    Mol Imaging Biol; 2017 Dec; 19(6):817-824. PubMed ID: 28341976
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours.
    Gaertner FC, Plum T, Kreppel B, Eppard E, Meisenheimer M, Strunk H, Bundschuh RA, Sinnes JP, Rösch F, Essler M.
    Nucl Med Biol; 2019 Feb; 76-77():1-9. PubMed ID: 31520872
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Preparation and Evaluation of [18F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [68Ga]Ga-DOTA/NOTA-NOC.
    Dam JH, Langkjær N, Baun C, Olsen BB, Nielsen AY, Thisgaard H.
    Molecules; 2022 Oct 12; 27(20):. PubMed ID: 36296411
    [Abstract] [Full Text] [Related]

  • 11. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.
    J Nucl Med; 2009 Sep 12; 50(9):1427-34. PubMed ID: 19690033
    [Abstract] [Full Text] [Related]

  • 12. 68Ga/177Lu-labeled DOTA-TATE shows similar imaging and biodistribution in neuroendocrine tumor model.
    Liu F, Zhu H, Yu J, Han X, Xie Q, Liu T, Xia C, Li N, Yang Z.
    Tumour Biol; 2017 Jun 12; 39(6):1010428317705519. PubMed ID: 28618966
    [Abstract] [Full Text] [Related]

  • 13. Preliminary PET/CT Imaging with Somatostatin Analogs [68Ga]DOTAGA-TATE and [68Ga]DOTAGA-TOC.
    Satpati D, Shinto A, Kamaleshwaran KK, Sarma HD, Dash A.
    Mol Imaging Biol; 2017 Dec 12; 19(6):878-884. PubMed ID: 28349291
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
    Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, Vonguggenberg E, Warwitz B, Virgolini IJ.
    Q J Nucl Med Mol Imaging; 2010 Feb 12; 54(1):68-75. PubMed ID: 20168288
    [Abstract] [Full Text] [Related]

  • 16. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.
    Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP.
    Semin Nucl Med; 2011 Jul 12; 41(4):314-21. PubMed ID: 21624565
    [Abstract] [Full Text] [Related]

  • 17. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.
    Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar RO, Araman A, Kanmaz B.
    Nucl Med Commun; 2013 Nov 12; 34(11):1084-9. PubMed ID: 23939265
    [Abstract] [Full Text] [Related]

  • 18. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors.
    Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, Spitzweg C, Boeck S, Unterrainer M, Gildehaus FJ, Böning G, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Bartenstein P.
    Eur J Nucl Med Mol Imaging; 2020 Apr 12; 47(4):870-880. PubMed ID: 31492994
    [Abstract] [Full Text] [Related]

  • 19. Feasibility and availability of ⁶⁸Ga-labelled peptides.
    Decristoforo C, Pickett RD, Verbruggen A.
    Eur J Nucl Med Mol Imaging; 2012 Feb 12; 39 Suppl 1():S31-40. PubMed ID: 22388621
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.